Business
The Moderna way to profit from CSL’s vaccine challengers – The Australian Financial Review
Why the technology behind Moderna’s vaccine stands to disrupt CSL and how the spectacular collapse of Theranos exemplifies the need for biotech investors to always…
Ogden says that while sceptics of Moderna have targeted its lack of experience and unproven technology, the growing evidence of progress supports the view that it will be able to execute on the mammoth task of validation and distribution.
And the market agrees. The Nasdaq-listed company’s shares have surged more than sixfold over the last 12 months, closing at $US127.03 at the end of last week after telling investors it had signed a deal with the European Union to supply up to 160 million doses…
-
Noosa News17 hours agoBrisbane vs Collingwood live blog: Richmond selects Noah Balta as unbeaten Lions prepare for Magpies test
-
General24 hours agoMinecraft mayhem: ‘Chicken jockey’ chaos reaches Australian cinemas
-
General18 hours agoCanberra man named as doctor accused of rape after suppression order lifted
-
Noosa News20 hours agoAustralians tell ABC’s Your Say how they saw the second leaders debate